In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


British Biotech PLC

Division of Ligand Pharmaceuticals Inc.

Latest From British Biotech PLC

Biocompatibles: The Perils of Re-Inventing a Public Company

The medical device industry is full of companies that started out focusing on one therapeutic area only to shift gears and apply their original or another technooloogy to a different clinical need. Indeed, Biocompatibles is now workiing on its third primary therapeutic areas--cancer--having previously sold off its first two businesses, in ophthalmology and then, convinced it was too far behind in drug-eluting stents, cardiovascular. This new growth area is being driven by the company's general expertise in polymer technology and drug delivery.
BioPharmaceutical Medical Device

Conforma Gets Confirmation: Modern methods validate an old-fashioned discovery approach

Conforma Therapeutics' recent research finding may well inspire other companies to combine the best of traditional and new drug discovery methods: the start-up identified an old, natural compound by its physiological properties, then through modern technologies deduced the reason that it works.
BioPharmaceutical Business Strategies

European Biotech M&A: Often Last Resort, but Welcome Nevertheless

Consolidation among Europe's biotech firms is picking up, but less for strategic reasons than simply to secure the cash to survive. Whatever the drivers, though, and however ruthless the concurrent cost- and program cutting, M&A should help create better adapted, bigger companies-something investors have long been calling for. Indeed for most merging companies, M&A is just the first step towards more strategic business-building moves in the near future.
BioPharmaceutical Europe

Acambis: Can Smallpox Sustain?

The UK's Acambis became one of a handful of European biotechs to post profits this year, boosted by a US government smallpox vaccine contract worth $428 million. The profitability label is a useful one these days: cautious investors find it easier to swallow R&D risk if accompanied by earnings. And Acambis' management has promised it can keep the company in the black, defying the skeptics. Near-term, it will leverage its smallpox franchise to secure further, and extended, government contracts. Beyond that, Acambis' pipeline of relatively low-risk products should start to come to fruition.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • British Biotech Pharmaceuticals Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Ligand Pharmaceuticals Inc.
  • Senior Management
  • Tony Weir, Dir., Fin.
    Peter Fellner, Chmn.
  • Contact Info
  • British Biotech PLC
    Phone: (44) 118 977 3133
    Oakdene Ct. 613 Reading Rd..
    Wokingham, RG41 5UA